The correlation between neurodegenerative disease and protein aggregation in the brain has long been recognized, but a causal relationship has not been unequivocally established, in part because a discrete pathogenic aggregate has not been identified. The complexity of these diseases and the dynamic nature of protein aggregation mean that, despite progress towards understanding aggregation, its relationship to disease is difficult to determine in the laboratory. Nevertheless, drug candidates that inhibit aggregation are now being tested in the clinic. These have the potential to slow the progression of Alzheimer's disease, Parkinson's disease and related disorders and could, if administered presymptomatically, drastically reduce the incidence of these diseases. The clinical trials could also settle the century-old debate about causality.
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. A century later, this question has been vigorously investigated and debated, but not definitively answered. Protein aggregation of some type is now also known to be a characteristic feature of Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and many less prevalent neurodegenerative diseases. However, the fibrillar deposits that are found in postmortem diseased brains -for example, the amyloid plaques noted by Alzheimer, the Lewy bodies of PD and related diseases, and the nuclear inclusions of HD -can be present in the brains of asymptomatic individuals and do not correlate to the severity of disease at time of death. Spurred on by a greater understanding of the in vitro protein fibrillization process, a search for a specific neurotoxic prefibrillar aggregate and the pathway by which it causes neuronal dysfunction, death and disease is underway.
The precise relationship between protein aggregates such as the extracellular amyloid plaques and intracellular neurofibrillary tangles that characterize the Alzheimer's disease (AD) brain and the neurodegeneration that produces symptoms has not been determined (Fig. 1) . The possibility that protein aggregation causes neurodegeneration (as opposed to resulting from it) returned to centre stage with the discovery that a gene linked to autosomal dominant familial AD encodes a precursor (amyloid precursor protein, APP) of the amyloid-β protein (Aβ) 2 . Aβ is a 4-kDa peptide that comprises the least soluble, fibrillar component of AD amyloid plaques 3, 4 . During the past 15 years, a working hypothesis has been developed implicating protein aggregation as the trigger of the cascade of events that result in neurodegeneration and disease 5 . This model, which is known as the 'amyloid hypothesis' , has evolved with our understanding of the process of protein aggregation and has withstood concerted efforts to disprove it. In recent years, the hypothesis has been generalized as it has become apparent that most neurodegenerative diseases are characterized by protein aggregates, albeit of varying composition. This review briefly summarizes the key experiments that led to the working hypothesis, but focuses on recent experimental findings that purport to test elements of the working model.
The amyloid hypothesis has been shaped by evidence drawn primarily from three disciplines: neuropathology, genetics and biophysics. Each class of evidence is powerful, but each also has limitations. Pathological studies have focused on defining and refining the correlation between protein deposits, neuronal dysfunction, neuronal loss and severity of symptoms at time of death. Because studies of human tissue rely on postmortem samples, it is difficult to glimpse the early stages of disease during which the triggering species is most likely to be observable. However, this critical period is theoretically observable in living patients by brain imaging. Recent advances towards the in vivo detection of amyloid plaques in human patients with AD [6] [7] [8] mean that it may soon be possible to follow the natural history of protein aggregation and correlate it with disease progression (Box 1) . In the meantime, studies of animal models have provided detailed information about certain phenotypes of the human disease 9, 10 . Genetic data are clearly relevant to human AD and have been instrumental in the building of a circumstantial case to support existing models of pathogenesis. The genes that have been linked to disease are predominantly of two types: familial and susceptibility factors. Several genes of the former type have been identified, and, when mutated, these cause rare, early-onset forms of disease. Examples include the genes encoding APP, which is involved in familial AD, and α-synuclein, which is involved in familial PD. Whether these monogenic subtypes are representative of the vast majority of cases, which are believed to originate from a complex mixture of genetic and perhaps environmental factors, is debatable (see below). The latter type of disease-gene link is based on a susceptibility factor, such as apolipoprotein-E genotype in AD 11 or UCH-L1 genotype in PD 12 . Although these susceptibility factors are found in many patients, it is difficult to translate their subtle effects into a working hypothesis.
Finally, biophysical studies have been increasingly influential in this field owing to their ability to provide a mechanistic rationale to better explain the effects of disease-causing mutations -for example, why the Aβ42/Aβ40 ratio is more critical than the total amount of Aβ produced 13 . The obvious shortcoming of such studies is that the idealized experimental systems that they require bear little resemblance to the human brain. Moreover, the pathological processes are difficult to study in vitro, because, unlike biologically necessary processes (such as the complement cascade) or structures (for example, the proteasome), protein aggregation has not been optimized by evolution and is difficult to reconstitute in an artificial environment (in fact, evolution has probably done its best to reduce protein aggregation).
This review discusses and evaluates a series of increasingly detailed hypotheses that seek to explain the relationship between protein aggregation and neurodegenerative disease. We focus on AD, because it set the historical course for the development of the field. AD is also the most prevalent human neurodegenerative disease, and, for that reason, is the subject of intense drug-development efforts. However, examples from other neurodegenerative diseases are discussed where appropriate. We also examine the state-of-the-art working hypotheses, asking what can be done to refine and clarify the current models, and more importantly, what needs to be done in order to produce disease-modifying treatments for neurodegenerative diseases and to identify presymptomatic individuals who could benefit from such treatments.
Fibrillar aggregates could be the cause or effect of disease
The two early hypotheses (Fig. 1 ) in this field were predicated on the fact that fibrillar deposits were the only observable proteinaceous abnormalities in postmortem human tissue. The two are mutually exclusive, but do not, as explained below, encompass all possibilities: both could be wrong. Although they differ in terms of the causal relationship between protein fibrils and disease, both posit that fibrillar aggregates and disease are linked.
As the list of neurodegenerative diseases characterized by fibrillar aggregates grew 14 , it became apparent that subtypes of several such diseases are not characterized by the presence of fibrillar deposits in the brain. This finding indicates that fibrillar deposits are not generally coupled to disease and, therefore, that hypotheses one and two are both incorrect. It is possible that diseases that do not show fibrillar aggregation, which include Gerstmann-Straussler syndrome (a genetic prion disease) 15 , autosomal recessive juvenile parkinsonism (AJPR, a juvenileonset form of PD) 16 and sporadic ALS 17 , are not representative of most neurodegenerative diseases. However, the number and size of plaques in a postmortem AD brains do not correlate with the severity of symptoms at the time of death 18, 19 , which also argues against hypotheses one and two. Finally, another fact that conflicts with the second hypothesis is that amyloid plaques are found throughout the cortex of many cognitively normal 70-year-olds 20 .
Fibrillar aggregates are an epiphenomenon of disease
So, a revised hypothesis is necessary to explain the qualitative, but not quantitative, correlation between fibrillar deposits and disease. This model (hypothesis number three, Fig. 2 ) allows for the extreme situations described above -prevalent deposits accompanied by little or no disease on the one hand and severe disease with little or no deposits on the other.
It has been estimated that neurodegeneration associated with AD and PD starts 5 to 10 years before symptoms warrant a diagnosis. In the case of PD, imaging studies have shown that loss of 50% of the substantia nigra's dopaminergic neurons is tolerated; symptoms typically appear when 70% have been lost 81 . The development of methods to diagnose these diseases presymptomatically has not been a commercial priority, because available therapies target only the symptoms, not the underlying disease. However, this situation is about to change, as the use of therapies that slow the underlying disease (Box 2) will be greatly increased if disease can be diagnosed and treated presymptomatically (Fig. 4) . As more genetic risk factors emerge, it will be possible to assess risk, but in order to justify treatment, it will be necessary to directly measure the disease process. This is possible for PD, because the affected region of the brain is localized and excellent methods for imaging dopaminergic neurons are available. However, in the case of AD, direct imaging of protein aggregates may provide a more sensitive measure. William Klunk of the University of Pittsburgh has developed a positron emission tomography imaging reagent that targets fibrillar amyloid plaques and allows their detection in vivo 6 . However, given that fibrillar amyloid occurs relatively late in the disease process, it would also be useful to develop analogous reagents that target early Aβ-derived aggregates. A recent study in transgenic AD mouse models 47 used classical biochemical separation methods to correlate a non-fibrillar Aβ-containing species (Aβ*56) with the appearance of an AD-like phenotype. An analogous study, correlating an early Aβ aggregate with the first clinical signs of AD, would require the development of new technology and would have enormous practical consequences. A time can be imagined when individuals with a relative risk of >2.0, on the basis of genetic factors, would be routinely imaged at the age of 50 using such a reagent (Fig. 4) . If abnormal Aβ aggregates were present, treatment with a disease-modifying drug could begin immediately. This approach might effectively 'cure' many cases of AD. According to this hypothesis, many different events (the lighting bolts in Fig. 2 ) could cause both fibril formation and disease. However, given that the fibrillar protein aggregates arise from a normally expressed protein (such as Aβ or α-synuclein) by a complex pathway, it is logical to start by postulating that a precursor to the fibrillar aggregates may be the triggering factor 21 . This hypothesis is supported by studies in animal models, which reinforce the conclusion that fibrillar deposits are not directly related to disease [22] [23] [24] , and in some cases demonstrate that fibrillar deposits and disease-like phenotype are anticorrelated. Thus, perturbations that increase deposits decrease the disease-like phenotype and vice versa 23, 25, 26 . The in vitro discovery and characterization of prefibrillar protein aggregates provided a framework for this hypothesis.
Protofibrils are early intermediates in fibril formation
Although conventional light microscopic analysis of postmortem AD brains revealed only fibrillar protein deposits, immunostaining with antibodies to Aβ allowed detection of another type of Aβ deposit, known as diffuse amyloid 27 . This deposit lacks fibrillar substructure and was proposed to be a precursor to fibrillar amyloid. In contrast to the fibrillar deposits, which can be extracted from the brain because of their unusual stability, diffuse amyloid proved impossible to extract and characterize 28 . Therefore, the first non-fibrillar Aβ aggregates to be characterized were produced in vitro, from synthetic Aβ.
Two groups, using complementary methods, demonstrated that Aβ produces non-fibrillar aggregates, which are consumed as fibrils are formed 29, 30 . These species were designated protofibrils, because the time dependence of their formation and the disappearance of their secondary structure (primarily β-sheet) were consistent with their being an intermediate in the fibrillization process (whether or not protofibrils are on the direct pathway from monomers to fibrils is still unclear). Notably, both groups reported that Aβ42 forms protofibrils more rapidly than Aβ40, which is consistent with the fact that Aβ42 is much more strongly correlated with the disease process.
Subsequently, other non-fibrillar Aβ aggregates have been described, including Aβ-derived diffusible ligands (ADDLs) 31 , Aβ amylospheroids 32 , membrane-associated Aβ oligomers and annular Aβ protofibrils 33, 34 . How these species are related to one another is difficult to determine, because the conditions for their formation and characterization vary widely (Fig. 3) . Furthermore, although it is likely that these metastable oligomeric species 35 assemble in a stepwise process involving The first of these is Elan's Aβ vaccine. Inoculation of mice with an Aβ-derived immunogen resulted in the reduction of amyloid plaques 82 and a degree of rescue of some AD-like phenotypes 24, 83 . In subsequent animal studies, it was shown that passive immunization, by infusion of Aβ-directed antibodies, has a similar effect 84 , leading to the hypothesis that the vaccine causes redistribution of Aβ from the brain into the periphery, where it can be degraded 85 (1) . A reduction in brain Aβ would slow or even stop new aggregation, leading to a decrease in the rate of neurodegeneration. In addition, such a reduction could lead to complete resolution of amyloid plaques, which seem to be in dynamic equilibrium with monomeric Aβ and thus may be actively cleared. A second strategy (2) involves the inhibition of all Aβ aggregation by binding monomeric Aβ with a small molecule (X; Neurochem's 'Alzhmed' (tramiprosate)) that is thought to be a proteoglycan mimic. This reduces amyloid-plaque formation in mouse models (and also rescues certain AD-like phenotypes) 86 . The compound is well-tolerated and can cross the blood-brain barrier. Phase II trials suggested that a subset of patients with mild AD experienced some improvement in cognitive measures after receiving treatment for more than 1 year (http://www.neurochem.com/ResearchActivities.htm). Phase III trials, the ultimate determinant of efficacy, are underway. A third strategy (3) involves the reduction of Aβ42 production from APP (and Aβ42 aggregation), by modulating γ-secretase/presenilin activity. This strategy originated with the epidemiological finding that chronic arthritis patients had a lower incidence of AD 87 . It was determined that the use of some, although not all, non-steroidal antiinflammatory drugs (NSAIDs) was responsible for this effect, and that the efficacy of NSAIDs did not correlate with their ability to inhibit cyclooxygenase 2 (COX2) 88 . Myriad Genetics (http://www.myriad. com) is developing a compound, MPC-7869 (R-flurbiprofen, known as 'Flurizan'), that is one component of the racemic drug Flurbiprofen (Ansaid) and is itself inactive with respect to COX2 inhibition. MPC-7869 has been shown to reduce the levels of Aβ42 in cell culture 89 and in animal models of AD 90 by modulating the activity of γ-secretase, and is currently being evaluated in phase III clinical trials. It is hoped that this compound will not exhibit the side-effect profile associated with COX2 inhibitors. In a phase II study, patients with mild AD showed a decreased rate of decline in several clinical measures of AD severity, although moderately affected patients showed no significant improvement. Several pharmaceutical companies have reported that γ-secretase inhibitors, which lower Aβ42 and Aβ40 by an active-site-directed mechanism, are entering phase II trials.
An alternative strategy to reduce aggregate levels involves the stimulation of aggregate degradation (possibly by autophagy). Finally, the idea that the promotion of fibril formation (at the expense, presumably, of protofibril) would be therapeutic is based on the aggresome proposal of Kopito 91 and has shown some merit in a Drosophila model of PD 25 and in cell culture. However, this strategy carries considerable risk, because fibrils themselves may be toxic 71 . low-molecular-weight oligomers, the relative importance of these is difficult to assess because they are too unstable to characterize [36] [37] [38] . The intermediacy of stable, structured oligomers is a common feature of in vitro fibrillization by many disease-associated proteins, including α-synuclein 39, 40 , huntingtin 41 and islet amyloid polypeptide 42, 43 , as well as by fibril-forming proteins that are unrelated to disease 44 . Non-fibrillar aggregates have also been isolated from cell culture 45, 46 , from the brains of animal models of AD 21, 47 and from diseased human brains [48] [49] [50] [51] . Annular pore-like aggregates have been observed during the in vitro fibrillogenesis of many well-characterized amyloid-forming proteins 52 . Annular α-synuclein-containing structures, similar in morphology to the structures formed in vitro, have been isolated from postmortem brain tissue of patients with multiple system atrophy (MSA) (ref. 51 and H.A.L., unpublished observations). MSA, like Parkinson's disease and diffuse Lewy-body disease, is characterized by α-synuclein deposition in the form of cytoplasmic Lewy bodies.
Fibrillar aggregates and disease may have a common cause
A revised model of pathogenesis, which takes into account the complexity of the fibrillization process, states that one perturbation, or a combination of several (Fig. 3, lightning bolt) , causes protofibril formation, fibril formation and disease. Whether fibril formation is caused by protofibril formation, as shown in Fig. 3 , or merely co-occurs with protofibril formation is not as important, from a drug development perspective, as defining the relationship between protofibril formation and disease (dashed arrows). It is tempting to speculate that protofibril formation may cause both fibril formation and disease, but first, the possibility that protofibril formation and disease are caused by elevated levels of monomer protein must be considered (hypothesis number four; Fig. 3 ).
Accumulation of protein monomers is not the cause
Neurodegeneration and the expression levels of certain disease-associated proteins are clearly related. For example, triplication 53 or duplication 54 of the α-synuclein gene causes PD, and overexpression to a lesser extent due to a promoter polymorphism increases an individual's risk of PD 55 . This dependence is consistent with aggregation being important for disease, but is it possible that the monomeric protein independently causes both aggregation and disease (Fig. 3, hypothesis number four) ?
Several facts indicate (but do not prove) that the monomeric proteins are non-toxic. First, the disease-linked proteins -such as α-synuclein and superoxide dismutase (SOD1, known to be involved in ALS) -are highly expressed in the normal brain. Second, the disease-linked proteins are not homologous at the level of primary sequence or native tertiary structure, making it difficult to imagine that this diverse group of monomeric proteins activates a common toxic mechanism. However, all of the aggregates are characterized by β-sheet secondary structure that may be responsible for shared mechanisms of toxicity. Third, many of the mutations that cause familial neurodegenerative diseases do not significantly alter the encoded protein's native structure, but reduce its stability and hence its steady-state level in vivo while accelerating its aggregation in vitro (this is well documented for AD 56 , PD 39,57-59 and ALS 60 ). For example, the level of mutant SOD1 in the blood of patients with familial ALS is considerably lower than the level of wild-type SOD1, which is inconsistent with the monomeric protein's being toxic (furthermore, the amount of mutant protein is inversely correlated with the aggressiveness of disease) 61 . Fourth, cell death in neurodegenerative diseases exhibits stochastic behaviour and seems to be highly dependent on the level of protein -that is, small changes in expression level have a notable effect on disease onset and progression 62 . This nonlinear dependence is not consistent with the protein monomer's being the pathogenic species, but is easily explained by a protein-aggregation mechanism.
Finally, three features of monogenic neurodegenerative diseases are inconsistent with the fourth hypothesis. First, the age of symptom onset in Huntington's disease does not depend on the dosage of the abnormal gene (in other words whether it is heterozygous or homozygous) 63 . This finding is inconsistent with hypothesis number four, but can be explained by a seeded-polymerization model in which aggregation is nucleated by the product of the abnormal gene, and the aggregate can then grow equally well with either the mutant or the wild-type protein 64 . Second, although an elevated level of plasma Aβ42 is a risk factor for sporadic AD 65 , several presenilin mutations linked to familial AD do not affect Aβ42 levels and decrease Aβ40 production (however, most familial-AD-linked presenillin mutations increase Aβ42) 66 . This effect is inconsistent with any hypothesis contending that Aβ42 and/or Aβ40 elevation alone causes familial AD.
Third, the fourth hypothesis is difficult to reconcile with a phenomenon observed in sporadic prion disease 67 and familial ALS 68, 69 , whereby mutations or polymorphisms on separate alleles of the gene encoding the aggregating protein (the prion protein and SOD1, respectively) modulate the resultant disease. This conflicts with the idea of a protein monomer's being responsible for neurotoxicity, in which case the effects of two mutations should be additive. All of the data discussed above are consistent with the idea that nonfibrillar protein aggregates cause disease (hypothesis number five; Fig.  3 ). This hypothesis explains the lack of a gene-dosage effect in HD. It also explains why lowering Aβ40 can cause familial AD -Aβ40 inhibits the fibrillization of Aβ42 (by stabilizing protofibrils) -and why raising the ratio of Aβ42 to Aβ40, whether by elevating Aβ42 or by lowering Aβ40, increases the rate of fibrillization 70 . Finally, the phenomenon of compound heterozygosity is consistent with the fifth hypothesis, because intermolecular interactions are critical for determining aggregation rate and disease onset and progression.
Protofibrillar aggregates may trigger disease
A demonstration that clinical status and the abundance of certain prefibrillar protein aggregates are not quantitatively correlated would disprove the fifth hypothesis. However, at present this experiment is not possible, because there are no available imaging methods capable of tracking the early stages of protein aggregation in vivo (Box 1). This hypothesis could also be disproved if a drug that could selectively inhibit Aβ oligomerization and fibrillogenesis did not slow disease progression. In fact, three very different therapeutic strategies for AD that each seek to inhibit Aβ aggregation have shown some promise in reducing AD symptoms in phase II clinical trials (Box 2). It is important to note that the fifth hypothesis suggests that if fibrils are non-toxic (this is still an open question 71 ) , compounds that promote the conversion of early aggregates into fibrillar aggregates could slow disease progression.
Several protofibrillar aggregates may be neurotoxic
Because it is not currently possible to directly correlate the amount of a discrete protein aggregate to a human disease (Box 1), efforts have focused on cellular and mouse models of disease. Discrete protein aggregates have been identified both by in vitro aggregation of diseaseassociated proteins and in materials extracted from the brains of mouse models 47 and human patients 50, 51 . It is important to note that, in all of these, the extraction procedures and analysis methods (sodium dodecyl sulphate polyacrylamide gel electrophoresis, SDS-PAGE) are known to influence the dynamic aggregation process 72, 73 . Thus, it is never clear whether the species being manipulated in the laboratory ever existed in the tissue of interest (in theory, imaging could clarify this; see Box 1). However, bearing this caveat in mind, several compelling correlations have recently been reported. In each of these, the monomeric protein does not affect the phenotype of interest (providing further evidence against the second hypothesis) and in many (but not all 71 ) cases, the fibrillar aggregate also has no effect.
Non-fibrillar Aβ preparations enriched in SDS-stable oligomers, spherical 4-6-nm aggregates and chain-like aggregates have all been shown to be toxic to cultured neurons, to inhibit hippocampal long-term potentiation (LTP) 31, 32, 36, 74, 75 , to impair synaptic functions and to disrupt cognition and learned behaviour in rats 47, 76 . Non-fibrillar α-synuclein aggregates inhibit proteasomal activity 77 and induce Golgi fragmentation 78 . Furthermore, non-fibrillar aggregate preparations produced from several amyloid-forming proteins, regardless of differences in their size and/or morphological distribution, have been shown to be toxic to cultured cells/neurons, suggesting that a wide range of different aggregate species may be neurotoxic.
The problem with all of the correlative studies done so far is that they each reduce a complex human disease to a single measurable phenomenon -for example, 'the memory dysfunction in AD results from LTP deficit' . This oversimplification is required in order to reach clear conclusions, but AD (and PD, ALS and other similar disorders) probably results from a combination of biochemical, cell biological and systemic events (such as LTP deficit) each of which may, in turn, be influenced by one or more aggregate species. Ultimately, postmortem pathological data from human clinical trials of drug candidates that target specific processes (Box 2) will clarify the situation. However, in order to obtain this data, we must recognize that our current level of understanding, although incomplete, is sufficient for the development of such drug candidates.
We can change the medical landscape
It is critical to recognize that the onset of the neurodegenerative-disease process -which proceeds from the start of neuronal dysfunction -typically predates the first recognition of symptoms by at least 5-10 years (Box 1). Thus, if the presymptomatic disease could be diagnosed and treated, the prevalence of symptomatic disease could be greatly reduced (Fig. 4) . Because most neurodegenerative diseases are genetically complex (HD, which is purely familial and monogenic, is the exception), presymptomatic diagnosis will require either the discovery of a peripheral marker for neurodegeneration that reacts earlier and is more sensitive than the traditional symptoms (for example, alteration of gene expression in the periphery), or that the process of protein aggregation be observable in the brain (Box 1). The development of useful imaging technology does not require that the relationship between aggregation and disease be explained in detail, only that a prefibrillar target be identified and that a target-specific probe exist. Once early protein aggregation has been detected, the patient will be treated with a disease-modifying drug designed to reduce the amount of aggregates in the brain. Once again, it would not be necessary to identify one specific target providing that the strategy used reduced all aggregation -for example, by reducing production of the aggregating protein (Box 2) or by stimulating aggregate clearance 38, 79, 80 . Ultimately, Alzheimer's 100-year-old question, "what is the relationship between protein aggregation and neurodegeneration?" cannot be answered until the effects of such compounds on human disease are evaluated. The clinical trials will be large, time-consuming, risky and expensive, but we cannot afford to wait. 
